Medical treatment of hereditary neuropathies

  • P. Young


Schwann Cell Erectile Dysfunction Spinal Muscular Atrophy Lipoic Acid Hereditary Neuropathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    The BDNF study group. (Phase 3) (1999) A controlled trial of recombinant methionyl human BDNF in ALS. Neurology 52:1427–1433Google Scholar
  2. 2.
    Bains JS, Shaw CA (1997) Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res Brain Res Rev 25:335–358PubMedCrossRefGoogle Scholar
  3. 3.
    Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297PubMedCrossRefGoogle Scholar
  4. 4.
    Bella AJ, Brock GB (2003) Tadalafil in the treatment of erectile dysfunction. Curr Urol Rep 4:472–478PubMedGoogle Scholar
  5. 5.
    Bradbury J (2004) Antiprogesterone hope for inherited neuropathy. Lancet Neurol 3:6PubMedGoogle Scholar
  6. 6.
    Carenini S, Maurer M, Werner A, Blazyca H, Toyka KV, Schmid CD, Raivich G, Martini R (2001) The role of macrophages in demyelinating peripheral nervous system of mice heterozygously deficient in p0. J Cell Biol 152:301–308PubMedCrossRefGoogle Scholar
  7. 7.
    Carson CC, 3rd (2003) Sildenafil: a 4-year update in the treatment of 20 million erectile dysfunction patients. Curr Urol Rep 4:488–496PubMedGoogle Scholar
  8. 8.
    Coleman M, Perry V (2002) Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci 25:532PubMedCrossRefGoogle Scholar
  9. 9.
    De Jonghe P, Timmerman V (2003) Anti-steroid takes aim at neuropathy. Nat Med 9:1457–1458PubMedGoogle Scholar
  10. 10.
    Devroe E, Silver PA (2004) Therapeutic potential of retroviral RNAi vectors. Expert Opin Biol Ther 4:319–327PubMedCrossRefGoogle Scholar
  11. 11.
    Duby JJ, Campbell RK, Setter SM, White JR, Rasmussen KA (2004) Diabetic neuropathy: an intensive review. Am J Health Syst Pharm 61:160–173; quiz 175-166PubMedGoogle Scholar
  12. 12.
    Dyck PJ, Swanson CJ, Low PA, Bartleson JD, Lambert EH (1982) Prednisone-responsive hereditary motor and sensory neuropathy. Mayo Clin Proc 57:239–246PubMedGoogle Scholar
  13. 13.
    Fenton CF, 3rd, McGlamry ED, Perrone M (1982) Severe pes cavus deformity secondary to Charcot-Marie-Tooth disease: a case report. J Am Podiatry Assoc 72:171–175PubMedGoogle Scholar
  14. 14.
    Fenton CF, 3rd, Schlefman BS, McGlamry ED (1984) Surgical considerations in the presence of Charcot-Marie-Tooth disease. J Am Podiatry Assoc 74:490–498PubMedGoogle Scholar
  15. 15.
    Folkers K, Simonsen R (1995) Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. Biochim Biophys Acta 1271:281–286PubMedGoogle Scholar
  16. 16.
    Folkers K, Wolaniuk J, Simonsen R, Morishita M, Vadhanavikit S (1985) Biochemical rationale and the cardiac response of patients with muscle disease to therapy with coenzyme Q10. Proc Natl Acad Sci U S A 82:4513–4516PubMedGoogle Scholar
  17. 17.
    Frostick SP, Yin Q, Kemp GJ (1998) Schwann cells, neurotrophic factors, and peripheral nerve regeneration. Microsurgery 18:397–405PubMedGoogle Scholar
  18. 18.
    Gould N (1984) Surgery in advanced Charcot-Marie-Tooth disease. Foot Ankle 4:267–273PubMedGoogle Scholar
  19. 19.
    Guenard V, Schweitzer B, Flechsig E, Hemmi S, Martini R, Suter U, Schachner M (1999) Effective gene transfer of lacZ and P0 into Schwann cells of P0-deficient mice. Glia 25:165–178PubMedGoogle Scholar
  20. 20.
    Hellstrom WJ (2003) Vardenafil: a new approach to the treatment of erectile dysfunction. Curr Urol Rep 4:479–487PubMedGoogle Scholar
  21. 21.
    Low PA (2002) Autonomic neuropathies. Curr Opin Neurol 15:605–609PubMedCrossRefGoogle Scholar
  22. 22.
    Lupski J, Wise C, Kuwano A, Pentao L, Parke J, Glaze D, Ledbetter D, Greenberg F, Patel P (1992) Gene dosage is a mechanism for Charcot-Marie-Tooth disease type 1A. Nat Genet 1:29–33PubMedCrossRefGoogle Scholar
  23. 23.
    Maier M, Berger P, Suter U (2002) Understanding Schwann cell-neurone interactions: the key to Charcot-Marie-Tooth disease? J Anat 200:357–366PubMedCrossRefGoogle Scholar
  24. 24.
    Martini R (2001) The effect of myelinating Schwann cells on axons. Muscle Nerve 24:456–466PubMedCrossRefGoogle Scholar
  25. 25.
    Maurer M, Kobsar I, Berghoff M, Schmid CD, Carenini S, Martini R (2002) Role of immune cells in animal models for inherited neuropathies: facts and visions. J Anat 200:405–414PubMedCrossRefGoogle Scholar
  26. 26.
    Naef R, Adlkofer K, Lescher B, Suter U (1997) Aberrant protein trafficking in Trembler suggests a disease mechanism for hereditary human peripheral neuropathies. Mol Cell Neurosci 9:13–25PubMedCrossRefGoogle Scholar
  27. 27.
    Naef R, Suter U (1999) Impaired intracellular trafficking is a common disease mechanism of PMP22 point mutations in peripheral neuropathies. Neurobiol Dis 6:1–14PubMedCrossRefGoogle Scholar
  28. 28.
    Ochs G, Penn RD, York M, Giess R, Beck M, Tonn J, Haigh J, Malta E, Traub M, Sendtner M, Toyka KV (2000) A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1:201–206PubMedCrossRefGoogle Scholar
  29. 29.
    Pappagallo M (2003) Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine. Clin Ther 25:2506–2538PubMedCrossRefGoogle Scholar
  30. 30.
    Passage E, Norreel JC, Noack-Fraissignes P, Sanguedolce V, Pizant J, Thirion X, Robaglia-Schlupp A, Pellissier JF, Fontes M (2004) Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 10:396–401PubMedCrossRefGoogle Scholar
  31. 31.
    Perea J, Robertson A, Tolmachova T, Muddle J, King RH, Ponsford S, Thomas PK, Huxley C (2001) Induced myelination and demyelination in a conditional mouse model of Charcot-Marie-Tooth disease type 1A. Hum Mol Genet 10:1007–1018PubMedCrossRefGoogle Scholar
  32. 32.
    Rusciani L, Severino E, Rusciani A (2002) Type A botulinum toxin: a new treatment for axillary and palmar hyperhidrosis. J Drugs Dermatol 1:147–151PubMedGoogle Scholar
  33. 33.
    Saifi GM, Szigeti K, Snipes GJ, Garcia CA, Lupski JR (2003) Molecular mechanisms, diagnosis, and rational approaches to management of and therapy for Charcot-Marie-Tooth disease and related peripheral neuropathies. J Investig Med 51:261–283PubMedGoogle Scholar
  34. 34.
    Sereda MW, Meyer zu Horste G, Suter U, Uzma N, Nave KA (2003) Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 9:1533–1537PubMedCrossRefGoogle Scholar
  35. 35.
    Wagey R, Lurot S, Perrelet D, Pelech SL, Sagot Y, Krieger C (2001) Phosphatidylinositol 3-kinase activity in murine motoneuron disease: the progressive motor neuropathy mouse. Neuroscience 103:257–266PubMedCrossRefGoogle Scholar
  36. 36.
    Williams LL, O’Dougherty MM, Wright FS, Bobulski RJ, Horrocks LA (1986) Dietary essential fatty acids, vitamin E, and Charcot-Marie-Tooth disease. Neurology 36:1200–1205PubMedGoogle Scholar
  37. 37.
    Young P, Suter U (2003) The causes of Charcot-Marie-Tooth disease. Cell Mol Life Sci 60:2547–2560PubMedCrossRefGoogle Scholar
  38. 38.
    Young P, Suter U (2001) Disease mechanisms and potential therapeutic strategies in Charcot-Marie-Tooth disease. Brain Res Brain Res Rev 36:213–221PubMedCrossRefGoogle Scholar

Copyright information

© Steinkopff Verlag Darmstadt 2005

Authors and Affiliations

  • P. Young

There are no affiliations available

Personalised recommendations